Loading…
← CockpitCompetitor Analysis › RPGLIFE.NS RPG Life Sciences LimitedOpen in the cockpit ↗

RPG Life Sciences LimitedRPGLIFE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum neutral 43
Mkt cap
$443M
US dollars, full cap
Free float
17%
of shares outstanding
$/day
$646,787
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.9 pp
WACC 13.6%
Hurdle
n/a
no reverse DCF
Close · INR₹2,502
1D-1.8%
1W-4.0%
1M-12.0%
3M-7.4%
6M+9.6%
YTD+7.8%
1Y+6.2%
ATR %4.5%
Beta0.70
52w lowhigh20.0% off high

What RPG Life Sciences does

Employees: 2,012

RPG Life Sciences at a glance

Size RPG Life Sciences (RPGLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $443M, the 904th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,502 on 18 Nov 2026.

Performance Over six months the shares gained 9.6%, against -18.4% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 14.7% over the last twelve months (peer median +8.5%); the operating margin is 17.3% (peer median 3.3%).

Valuation It trades at 5.3× enterprise value to sales against a peer median of 2.6× (5th most expensive of 21).

Capital Return on invested capital runs 0.9 points below its cost of capital (13.6% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026RPGLIFE.NS 109Peer median 82
Six months, rebased to 100: RPG Life Sciences against the median of its 20 peers (local-currency closes).

RPG Life Sciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹7.64B₹7.04B₹6.50B₹5.79B₹5.10B
Revenue growth—+8%+12%+13%—
Gross profit₹3.21B₹2.44B₹2.45B₹2.07B₹1.70B
EBITDA₹1.56B₹1.47B₹1.60B₹1.27B₹1.03B
Net income₹1.09B₹1.15B₹1.83B₹877M₹676M
Free cash flown/a-₹800,000₹444M₹261M₹606M
Capital expendituren/a₹654M₹360M₹692M₹327M
Total debt₹264M₹200M₹0₹0₹100,000

Quarterly statements and history in the cockpit →

RPG Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-30%-20%-10%0%002462603811000640002900000788000518GUFICBIO688136605077688117PHAT002923ASMB600613ZOTAOVID0484104114601089RPGLIFE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. RPG Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×150×002462603811000640002900000788000518605077688117PHATASMBZOTAOVID0484104114RPGLIFE.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. RPG Life Sciences is the large dot.

RPG Life Sciences competitors and peer comparison

How RPG Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

RPG Life Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureRPGLIFE.NSPeer medianRank in peer set
1-month return-12.0%-10.9%9th lowest of 21
6-month return+9.6%-18.4%2nd highest of 21
Distance from 52-week high-20.0%-43.9%3rd highest of 21
Revenue growth (TTM)+14.7%+8.5%9th highest of 21
Operating margin17.3%3.3%3rd highest of 21
EV / Sales5.3×2.6×5th most expensive of 21
ROIC minus cost of capital-0.9 pp-1.6 pp10th highest of 20
EV / EBITDA25.9×14.5×most expensive of 4
Net debt / EBITDA-1.7×2.0×least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%5.3×n/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%0.2×-9.9%-3.4%
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%3.4×1.3%+1.3%
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a

Questions

Which companies are RPG Life Sciences's closest peers?
The cockpit's peer set: Cachet Pharmaceutical (002462.SZ), Zhejiang Chengyi Pharmaceutical (603811.SS), Dong-A Socio (000640.KS), Harbin Medisan Pharmaceutical (002900.SZ), PKU Healthcare (000788.SZ), Jiangsu Sihuan Bioengineering (000518.SZ), Pulike Biological Engineering (603566.SS), Gufic Biosciences (GUFICBIO.NS).
Is RPG Life Sciences expensive compared with its peers?
On ev / sales it trades at 5.3× against a peer median of 2.6×, 5th most expensive of 21 in its peer set.
How has RPG Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +9.6% against -18.4% for the median peer; over one year +6.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.